Captor Therapeutics SA
Michal J. Walczak has a diverse work experience in the field of scientific research and entrepreneurship. Michal J. co-founded Alphamoon in September 2017, where they served as a co-founder until January 2019. Prior to that, they were a Chief Scientific Officer and co-founder at Captor Therapeutics SA, starting in October 2017. From July 2015 to June 2017, they worked as a Research Fellow at the Friedrich Miescher Institute for Biomedical Research. Michal J. also worked as a Postdoctoral Fellow at ETH Zürich from November 2014 to February 2015.
Michal J. Walczak completed a Bachelor of Science (B.Sc.) in Biotechnology from the University of Wroclaw from 2004 to 2008. Michal J. then pursued a Master of Science (MSc) in Biophysics at the University of Virginia from 2008 to 2009. From 2010 to 2014, they obtained their PhD in Biophysics and Structural Biology from ETH Zürich.
This person is not in any teams
This person is not in any offices
Captor Therapeutics SA
Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable.